

Metadata of the chapter that will be visualized online

Chapter Title	Affinity Tags in Protein Purification and Peptide Enrichment: An Overview	
Copyright Year	2014	
Copyright Holder	Springer Science+Business Media, LLC	
Author	Family Name	Pina
	Particle	
	Given Name	Ana Sofia
	Suffix	
Author	Family Name	Batalha
	Particle	
	Given Name	Íris L.
	Suffix	
Corresponding Author	Family Name	Roque
	Particle	
	Given Name	Ana Cecília A.
	Suffix	
	Division	Departamento de Química
	Organization	Universidade Nova de Lisboa, REQUIMTE
	Address	2829-516, Caparica, Portugal
Abstract	<p>The reversible interaction between an affinity ligand and a complementary receptor has been widely explored in purification systems for several biomolecules. The development of tailored affinity ligands highly specific towards particular target biomolecules is one of the options in affinity purification systems. However, both genetic and chemical modifications on proteins and peptides widen the application of affinity ligand-tag receptor pairs towards universal capture and purification strategies. In particular, this chapter will focus on two case studies highly relevant for biotechnology and biomedical areas, namely, the affinity tags and receptors employed on the production of recombinant fusion proteins and the chemical modification of phosphate groups on proteins and peptides and the subsequent specific capture and enrichment, a mandatory step before further proteomic analysis.</p>	
Keywords (separated by “-”)	Recombinant proteins - Fusion proteins - Affinity tags - Affinity purification - Phosphoproteomics	

Affinity Tags in Protein Purification and Peptide Enrichment: An Overview 2 3

Ana Sofia Pina, Íris L. Batalha, and Ana Cecília A. Roque 4

Abstract 5

The reversible interaction between an affinity ligand and a complementary receptor has been widely explored in purification systems for several biomolecules. The development of tailored affinity ligands highly specific towards particular target biomolecules is one of the options in affinity purification systems. However, both genetic and chemical modifications on proteins and peptides widen the application of affinity ligand-tag receptor pairs towards universal capture and purification strategies. In particular, this chapter will focus on two case studies highly relevant for biotechnology and biomedical areas, namely, the affinity tags and receptors employed on the production of recombinant fusion proteins and the chemical modification of phosphate groups on proteins and peptides and the subsequent specific capture and enrichment, a mandatory step before further proteomic analysis. 6 7 8 9 10 11 12 13 14

Key words Recombinant proteins, Fusion proteins, Affinity tags, Affinity purification, Phosphoproteomics 15 16

1 Introduction 17

The production of recombinant proteins became possible with the emergence of DNA technology in the 1970s [1], which contributed for the facile manipulation of DNA sequences and consequently for the production of an encoded protein in different hosts (e.g., bacterial, fungal, and eukaryotic host cells) [2]. Bacterial hosts are usually more attractive due to their simplicity, well-established methods for genetic manipulation, high product yields, rapid expression, and cost-effectiveness [3]. However, a major drawback is that protein expression can lead to the formation of insoluble aggregates. These aggregates, termed inclusion bodies (IBs), are formed by unfolded or highly misfolded polypeptides [3]. In order to address these challenges, target proteins can be fused to affinity tags to enhance the fusion partner solubility and proper folding and also overcome problems as protein instability and host cell toxicity [4, 5]. However, the main purpose of introducing affinity 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

this figure will be printed in b/w




Fig. 1 Production and purification of recombinant protein scheme, involving (1) insertion of recombinant DNA in host cells and transformation process, (2) cloning process, (3) selection of the host cells containing recombinant DNA, (4) growth of the host cells, (5) upscaling, (6) fusion protein purification through affinity chromatography, (7) recognition of fused protein by the affinity ligand through affinity tag, and (8) elution of the purified fusion protein

tags is to facilitate the purification of recombinant proteins (Fig. 1). The tag usually presents high affinity for a specific biological or chemical ligand immobilized onto a chromatographic matrix. Besides their main applications in purification and as solubility enhancers, affinity tags may be used in many other applications, including labeling for imaging and localization studies, protein-protein interactions, and subcellular localization or transduction [4].

2 Affinity Tags in the Purification of Recombinant Proteins

Affinity tags vary in size, going from a single amino acid to whole proteins [6, 7]. The affinity tag can be placed at both ends of the protein of interest, with the majority being placed at the C-terminal [7]. These tags must exhibit some characteristics as stability, selectivity, and formation of reversible molecular complex with inexpensive, physically and chemically stable ligands/binding partners [7, 8]. Ideally, the dissociation of the tag-receptor system should be performed at mild conditions to facilitate the recovery of the fusion protein [8].

t1.1 **Table 1**
t1.2 **Summary of short peptides used as affinity tags**

t1.3	Type of affinity tag	Size	Ligand	References
t1.4	<i>Enzymes</i>			
[AU1]t1.5	β -Galactosidase	116 kDa	Thiogalactosidyl Sepharose	[114]
t1.6	Glutathione S-transferase	26 kDa	Glutathione Sepharose	[12]
t1.7	Chloramphenicol acetyl transferase	24 kDa	Chloramphenicol Sepharose	[115]
t1.8	Thioredoxin	12 kDa	Require a purification tag	[22]
t1.9	<i>Polypeptide-binding proteins</i>			
t1.10	Staphylococcal protein A	14–31 kDa	IgG	[33]
t1.11	ZZ domains	7 kDa	Protein A	[34]
t1.12	Albumin-binding domain	75–25 kDa	I-Albumin	[116]
t1.13	Phosphate-binding domain	34 kDa	Hydroxyapatite	[117]
t1.14	<i>Carbohydrate-binding domains</i>			
t1.15	Maltose-binding domain	40 kDa	Cross-linked amylose	[19]
t1.16	Cellulose-binding domain	~100 kDa	Cellulose	[118]
t1.17	Starch-binding domain	133 aa	Starch	[119]
t1.18	Exoglucanase CBD	128 aa	Cellulose	[120]
t1.19	<i>Other protein tags</i>			
t1.20	N-Utilization substance (NusA)	55 kDa	Require a purification tag	[29]
t1.21	Small ubiquitin modifier (SUMO)	11 kDa	Require a purification tag	[24]

Currently, there are a wide range of developed affinity tags to be used on the production and purification of recombinant proteins, and it is possible to assemble these affinity tags in two main groups, the protein affinity tags and the peptide affinity tags. The protein affinity tags enclose enzymes (e.g., GST), polypeptide-binding proteins (e.g., SpA), and carbohydrate-binding domains (e.g., MBP, CBD) (Table 1). The use of small peptide tags presents advantages over larger tags in terms of metabolism of the host cell, as less energy is consumed [8]. Also, short tags are less likely to interfere with the structure and function of the target protein; therefore, they may not need to be subsequently removed [8]. The small peptides used as affinity tags fall into two categories: the peptides that bind to small ligands (e.g., poly-arginine and poly-histidine) and the peptide tags that are recognized by proteins (e.g., FLAG) (Table 2). The affinity tags based on small peptides can also be categorized in (a) metal affinity tags, (b) charged peptides, (c) epitope peptides, (d) protein-binding peptides, and (e) streptavidin-binding proteins [4, 6–8].

The presence of the affinity tag may affect characteristics or functions of the target protein, and, depending on its final

t2.1 **Table 2**
t2.2 **Summary of protein native domains as affinity tags**

t2.3	Type of affinity tag	Tag sequence	Ligand	References
t2.4	<i>Metal affinity tags</i>			
t2.5	Poly-His	HHHHHH	Ni ²⁺ -NTA, CO ²⁺ -CMA	[39, 41]
t2.6	FlAsH tag	CCXXCC	Bis-arsenical fluorescein dye FlAsH	[121]
t2.7	HAT	KDHLIHVHLEEHAAHAN	CO ²⁺ CMA	[122]
t2.8	<i>Charged peptides</i>			
t2.9	Poly-Arg	5–15 aa (R)	Anionic resins	[123]
t2.10	Poly-Asp	5–16 aa (D)	Cationic resins	[124]
t2.11	Poly-Cys	4 aa (C)	Thiopropyl Sepharose	[125]
t2.12	Glu	1 aa (E)	Cationic resins	[126]
t2.13	Poly-Phe	11aa (E)	IEC	[127]
t2.14	<i>Epitope peptides</i>			
t2.15	FLAG™	DYKDDDDK	mAb M1, M2	[50, 128]
t2.16	c-myc	EQKLISEEDL	mAb 9E10	[51]
t2.17	T7	MASMTGGQMG	Anti-T7 9E10	[52, 53]
t2.18	<i>Protein-binding peptides</i>			
t2.19	S-tag	KETAAAKFERGHMDS	S-protein	[58]
t2.20	Calmodulin-binding protein	KRRWKKNFIAVSAANRFKKISSSGAL	Calmodulin	[60, 63, 64]
t2.21	<i>Streptavidin-binding proteins</i>			
t2.22	Bio tag	LGIFEAMKMEWR	Streptavidin/avidin	[129]
t2.23	Strep-tag	SAWRHPQFGG	Streptavidin	[65, 66]
t2.24	Strep-tag II	WHPQFEK	Strep-Tactin	[70]
t2.25	Avi tag	GLNDIFEAQKIEWHE	Streptavidin/avidin	[129]
t2.26	Nanotag	DVEAWLGAR	Streptavidin/avidin	[130]

70 application, it might be necessary to remove the tag (Table 3) [8].
 71 Specifically, in case of therapeutic proteins, there is a demand for
 72 tag cleavage as protein function can be lost and its integrity and
 73 biological activity are not achieved [5]. A variety of peptidases and
 74 other chemical methods are available for tag cleavage [9]. However,
 75 enzymatic methods may lead to unwanted consequences as the
 76 incomplete cleavage by the protease or the retention of additional
 77 amino acids in the fusion protein sequence from the cleavage site.
 78 Also, these enzymatic methods can contribute to increase the costs
 79 of the manufacturing process. Nowadays, there are other emerging
 80 alternatives such as self-cleaving tags [10, 11] used to overcome
 81 some drawbacks of the existent methods.

t3.1 **Table 3**
 t3.2 **Summary of enzymatic and chemical methods for tag removal**
 t3.3 (\downarrow = indicated chemical cleavage site; X = unspecific amino acid)

t3.4	Cleavage agent	Cleavage specificity	References
t3.5	<i>Enzymes</i>		
t3.6	Exopeptidases		
t3.7	Carboxypeptidase A	Poly H— \downarrow —X	[41]
t3.8	Carboxypeptidase B	Poly R— \downarrow —X	[131]
t3.9	Aminopeptidase I	EAE— \downarrow —X	[126]
t3.10	Endopeptidases		
t3.11	Enterokinase	DDDDK— \downarrow —X	[73]
t3.12	Factor Xa	IEGR— \downarrow —X	[75]
t3.13	Thrombin	LVPR— \downarrow —X	[76]
t3.14	TEV protease	EQLYFQ— \downarrow —X	[74]
t3.15	SUMO	SUMO tertiary structure	[25]
t3.16	<i>Chemical</i>		
t3.17	Cyanogen bromide	XM— \downarrow —X	[132]
t3.18	Hydroxylamine	XN— \downarrow —G	[133]
t3.19	Acetic acid	XN— \downarrow —P	[134]

3 Proteins as Affinity Tags

82

One of the classes of affinity tags consists of proteins or large peptides. Protein affinity tags can be divided in solubility-enhancing tags and purification tags. The solubility of the target proteins produced in bacterial hosts is the bottleneck of the production of recombinant proteins. Therefore, a few fusion proteins are already used to enhance protein expression and solubility of the target. Examples of these tags include glutathione S-transferase (GST), maltose-binding protein (MBP), staphylococcal protein A (SpA), thioredoxin A (Trx), small ubiquitin-related modifier (SUMO), and N-utilization substance A (NusA) [5]. GST and MBP tags not only improve the solubility of their fusion partners but also increase the efficiency of protein purification. GST tag is a 26 kDa protein derived from *Schistosoma japonicum* and belongs to a family of enzymes that can modify toxic substances by transferring sulfur from glutathione [12]. The proteins fused to GST tag can be purified from crude extracts by using affinity chromatography through the glutathione immobilized on the solid support [12]. The bound fusion proteins can be eluted under mild conditions through a competitive elution with reduced glutathione [12, 13]. Other main advantages of this tag include the protection and stabilization of the recombinant protein against intracellular protease cleavage in

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104 the expression host, the cost-effectiveness of the affinity resins, and
105 the use of mild conditions on the elution step [14]. Despite being
106 considered a solubility-enhancing tag, when used as a partner of
107 oligomeric proteins, hydrophobic regions enriched proteins, or
108 with proteins larger than 100 kDa, the solubility of the target pro-
109 tein is poor, as the expression of the fusion proteins is a high meta-
110 bolic burden for the host cell, contributing for an insoluble form
111 expression [15]. GST tag has been successfully used on protein-
112 DNA binding studies and protein-protein interactions [16].

113 MBP is a 42 kDa periplasmic protein involved on the maltose
114 transport system of *E. coli*, being responsible to transport maltose
115 and maltodextrins across the cytoplasmic membrane [17]. The
116 one-step purification is based on the strong affinity of MBP with
117 cross-linked amylose—a low-cost matrix. Also the bound tag can
118 be removed by using non-denaturing conditions (e.g., competitive
119 elution with maltose) [18, 19]. One of the greatest advantages of
120 using this tag is that MBP is an impressive solubilizing agent due
121 to the evidence that this tag can act as general molecular chaperone
122 preventing the self-aggregation of the fusion partner [20, 21].

123 The other solubility-enhancing tags already mentioned present
124 a higher impact on the solubility of the fusion partner; however, the
125 use of these tags requires additional affinity tags for use in protein
126 purification. TrxA is a small protein with 11.675 kDa, belongs to a
127 family of oxidoreductases, and presents in its active site a redox
128 couple for a number of biological reactions [22]. This tag allows a
129 high overall gene expression but lacks the formation of inclusion
130 bodies. In particular, the production of wide variety of secreted
131 mammalian cytokines and growth factors fused to the tag C-terminal
132 was possible in a soluble form using *E. coli* as a host [13, 23].
133 Overall, TrxA presents robust folding properties that contribute for
134 this tag to be a covalently joined molecular chaperone [13]. Also,
135 TrxA is a cytoplasmic protein and presents an inherent thermal sta-
136 bility, and these characteristics become helpful purification tools,
137 facilitating the recovery of the fusion partner of the cell by osmotic
138 shock and enabling heat treatments [23]. However, the purification
139 can be facilitated by using an extra affinity purification tag.

140 The SUMO protein is involved in posttranslational modifica-
141 tions in eukaryotic cells through the covalent binding to lysine side
142 chains of the target protein, and this presents high relevance on
143 various cellular processes (e.g., nuclear-cytosolic transport, apop-
144 tosis, and stability) [24, 25]. Once fused to the N-terminal of the
145 partner, it greatly promotes the target protein correct folding and
146 solubility when compared to untagged version [26]. Although this
147 tag also needs an additional tag for purification, it presents an
148 attractive feature that is the recognition by a SUMO protease (*S.*
149 *cerevisiae* Ulp1). This SUMO protease recognizes SUMO confor-
150 mation, more specifically the conserved Gly-Gly motif [25].
151 Although this technology is an effective tool for prokaryotic hosts,
152 in eukaryotic hosts there is the drawback of the natural occurrence

of SUMO-tag cleavage by the SUMO proteases in vivo [26, 27]. NusA is a 55 kDa transcription elongation and termination factor that modulates transcription by enhancing and pausing at some sites [28, 29]. Recently, it was reported that NusA is also involved in the coordination of cellular responses to DNA damage [30]. NusA is one of the largest proteins being used as carrier protein; however, it presents good solubilizing characteristics and high expression levels [31]. Moreover, this tag increases solubility of proteins (e.g., human interleukin-3) that were being produced as IBs by itself or fused to other tags (TrxA) [31]. This might be related with their biological activity. Once again, this tag is a solubility tag and cannot be purified with a specific affinity matrix, requiring a purification affinity tag [31, 32].

Other protein tags used to increase solubility or to facilitate purification include SpA and its derivatives (Z domain or Z tag) [5]. The SpA protein is present on the surface of the gram-positive bacterium *Staphylococcus aureus* and mainly interacts with the constant region (Fc) of most mammalian class G immunoglobulins (IgG) [33]. This protein tag has been used for the purification of a variety of fusion proteins produced in different hosts such as *E. coli*, yeast, CHO cells, baculovirus-infected insect cells, and plant cells, by using IgG affinity chromatography [34, 35]. The use of this tag presents several advantages, namely, proteolytic stability, the absence of disulfide bonds, and the presence of inherent high solubility [34]. The major drawback is related with the fragility of IgG as a ligand, contributing for ligand leakage and consequently end-product contamination [34]. The Z domain tag emerged as a mutated version of B domain, which is a homologous domain of SpA with high affinity for IgG. This affinity tag has been developed to improve the resistance of undesirable cleavage of the purified fusion protein when using chemical tag removal strategy [36]. Also in this case, the main disadvantages associated with this technology are regarding the immobilized binding partner (e.g., IgG) which presents high costs of production and purification, poor stabilization under sterilization and cleaning-in-place conditions, as well as potential leakage and end-product contamination.

The Z domain was also engineered to create the Z tag (basic or acidic), a highly charged domain to be used on the purification of recombinant protein through ion-exchange chromatography [37, 38]. The Z_{basic} tag has been employed on matrix-assisted refolding strategies of proteins that were solubilized with chaotropic agents after being produced as inclusion bodies [37].



4 Peptides as Affinity Tags

4.1 Metal Affinity Peptides

Immobilized metal affinity chromatography (IMAC) was introduced in 1975 by Porath and co-workers, being this type of chromatography based on the affinity between proteins and heavy metal

this figure will be printed in b/w

CRUDE EXTRACT
CONTAINING His
TAGGED PROTEIN



IMAC COLUMN




Fig. 2 Principle of protein purification through histidine affinity tag

199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216

ions (Zn^{2+} , Cu^{2+} , Ni^{2+}) [39]. This type of chromatography exploited the formation of stable complexes in aqueous solution between histidine (His) and cysteine (Cys) residues and zinc and copper [39]. After this, Hochuli et al. developed a new metal chelate affinity resin that once charged with nickel ions (Ni^{2+} -NTA) presents selectivity for neighboring His of proteins or peptides [40].

Subsequently, Hochuli et al. were also the pioneers on using a poly-histidine peptide (His-tag) genetically fused to the mouse dihydrofolate reductase protein and then produced in *E. coli* and purified on Ni^{2+} -NTA adsorbent with a subsequent His-tag removal by carboxypeptidase A [41]. Nowadays, the purification by using His-tag is one of the most used methodologies for protein purification and has been extensively described (Fig. 2) [42–44]. The main advantages of IMAC technology are related with high protein loading capacity, ligand stability, and lower costs. Also, this technology can be easily scaled up with reproducibility and affordable costs [42]. Other advantage of using IMAC for the purification of recombinant proteins is the compatibility with denaturant agents

for the solubilization and refolding of insoluble protein aggregates produced in *E. coli* host. IMAC technology has been described as a successful strategy for the one-step refolding of His-tagged proteins [45]. The major drawback of using a metal affinity tag is the metal ion leakage that leads to metal contamination of the end product. These metal ions are toxic, and therefore additional steps of purification are required, especially for therapeutic proteins. Moreover, the metal resin disposal constitutes an environmental problem [42].

Although IMAC has been used mainly for protein purification, different applications have been explored such as protein refolding and solubilization [45], protein microarrays [46–48], and phage display [49]. In this last application, phage display-derived peptide sequences were developed to bind to a novel class of chelating ligands complexed with Ni²⁺ [49]. These chelating agents are based on 1,4,7-triazacyclononane (TACN) structure and have been chosen to overcome ligand leaching in IMAC purification.

4.2 Epitope Peptides

Epitope peptides are used as tags but usually not for purification purposes because the affinity matrices are antibody based, which contributes for higher purification costs [4]. The most frequently antigenic peptides used are Flag-tag [50], c-myc [51], T7 epitope tag [52, 53], and Softags [54].

The Flag-tag is an eight-amino acid peptide with a hydrophobic sequence consisting of DYKDDDDK [50]. The Flag technology allows a rapid purification of fusion proteins in a mild, highly specific, and calcium-dependent affinity chromatography procedure with an Anti-Flag M1 monoclonal antibody immobilized on the affinity support [50]. One of the features of this tag is the recognition of the five C-terminal amino acids of the peptide sequence by the protease enterokinase, facilitating tag removal [50]. Main drawbacks of this system are related with ligand leakage and stability due to their own natural character and low scalability. Also, this system cannot be used for the purification of fusion proteins produced as IBs because denaturant agents are required. Although this tag presents a highly specific sequence for enterokinase recognition, unwanted cleavage may occur in the presence of contaminant proteases [50].

Softags are epitope tags used for immunoaffinity chromatography which present high affinity for “polyol-responsive” monoclonal antibodies (mAbs) [54]. These mAbs present a particular feature regarding the elution conditions, being possible to use mild conditions supplemented with a low molecular weight polyol (e.g., ethylene glycol) and a non-chaotropic salt [5, 54]. Softag 1 is a 13-amino acid sequence near the C-terminal of the β' subunit of *E. coli* RNA polymerase [55]; Softag 2 is a repeat heptapeptide found on C-terminal of RNA polymerase I [56]; and Softag3 is an epitope near the N-terminal of human transcription factor [57].

263 **4.3 Protein-Binding** 264 **Peptides**

265 S-peptide tag is a 15-amino acid sequence polypeptide resultant
266 fragment from the cleavage of ribonuclease A by the protease sub-
267 tilisin. The other remaining product is S-protein [58]. S-peptide
268 binds to S-protein with high affinity, and this interaction allows the
269 efficient affinity purification of recombinant proteins [58, 59].

270 Calmodulin-binding protein (CBP) is a calcium-binding pro-
271 tein that plays a key role as a regulator on a wide range of calcium-
272 dependent intracellular processes [60, 61]. Calmodulin-binding
273 unit is a 26-amino acid peptide derived from the carboxyl-terminal
274 of rabbit skeletal muscle myosin light chain kinase [62, 63]. This
275 peptide binds to calmodulin with a nanomolar affinity and is also
276 calcium dependent [60–63]. The elution can be carried out under
277 milder conditions and requires a calcium-chelating agent such as
278 ethylene glycol tetraacetic acid (EGTA) [60, 63]. This tag was
279 found out to be a versatile tag for antibody fragments [64].
However, its use in eukaryotic cells is hampered by its interference
in calcium signalling pathways [5].

280 **4.4 Streptavidin-** 281 **Binding Peptides**

282 The Strep-tag is a nine-peptide sequence (AWRHPQFGG) and
283 was originally developed by selection from a genetic peptide library
284 for its capability to bind to streptavidin protein in a highly specific
285 and reversible manner [65, 66]. Strep-tag recognizes the same
286 pocket of streptavidin as biotin, the natural ligand, allowing one-
287 step purification on immobilized streptavidin columns. However,
288 the original Strep-tag is needed to be fused only to the C-terminal
289 of the recombinant protein [67, 68]. A new improved version—
290 Strep-tag II, an eight-residue-peptide sequence (WSHPQFEK)—
291 was developed and optimized to overcome this constrain and also
292 presents affinity for streptavidin [67, 69]. Simultaneously, pro-
293 gresses have been made to optimize the respective chromato-
294 graphic matrices, and an engineered streptavidin support with
295 improved binding capacity (Strep-Tactin) has been developed
296 [70]. The main advantages of these systems are the resistance to
297 host cell proteases, the fact that the binding is not dependent on
298 metal ions, the elution that can be carried out at mild conditions,
299 and the biological inertness of this tag [70].

300 A new streptavidin-binding protein (SBP) was also developed
301 for the purification of recombinant proteins [71, 72]. This SBP tag
302 presents a sequence of 38 amino acids long with a nanomolar affini-
303 ty for streptavidin. The main applications of this tag are in high-
304 throughput protein expression and purification procedures,
existing already in several streptavidin-derivatized materials (plates,
beads, enzymes, fluorophores, etc.) commercially available [71].

305 **5 Tag Removal**

306 The removal of the affinity tag can be carried out by harsh chemical
307 treatments (e.g., cyanogen bromide or hydroxylamine) or by enzy-
308 matic cleavage, with the latter being preferred since it can be

performed under physiological conditions [6]. The chemical treatment presents significant drawbacks such as protein denaturation and side chain modification of amino acids in the target protein [6]. Several endoproteases have been utilized for tag removal [9], such as enterokinase [73], tobacco etch virus (TEV) [74] Factor Xa [75], thrombin [75, 76], and SUMO protease [25]. Enterokinase (EK) is a serine proteinase constituted by a high chain and a light chain linked by a disulfide bond. This enzyme presents high specificity for the (Asp)₄-Lys sequence, which contributes for a useful tool for fusion protein cleavage [73, 77]. Factor Xa and thrombin are trypsin-like serine proteases, and both recognize specific amino acid sequences (Table 3) [75]. TEV is a 49 kDa proteinase of tobacco etch virus (TEV) that cleaves the polyprotein derived from the TEV genomic RNA at five locations [74]. Most of these enzymes are able to cleave without requiring a specific sequence at the C-terminal, allowing for the complete removal of the tag [6, 9]. The major drawback associated with these enzymes is related with the high enzyme/protein ratios and the long incubation times required. Moreover, for an efficient tag removal, it is also necessary to take into account the absence of cryptic sites recognized by endoproteases in the native protein sequence [9].

Tag cleavage by using enzymatic or chemical methods always requires additional purification steps that contribute for the higher costs. In this way, other emerging technologies have been developed, namely, self-cleaving tags. There are different types of self-cleaving tags, such as inteins, sortase A, N-terminal protease, and FrpC module [10, 11]. In this particular case, these tags present inducible proteolytic activity under certain conditions as pH and/or temperature shift and addition of specific reagents (e.g., dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), Ca²⁺) [11]. Although these self-cleaving tags seem to be attractive from the economic point of view, there are still a few drawbacks associated with premature cleaving and consequently target-protein losses and minor product compatibility with cleaving conditions [10].

6 Affinity Tags for the Enrichment of Phosphorylated Proteins and Peptides


Posttranslational modifications (PTMs) are involved in the regulation of several cellular processes, such as gene expression, signal transduction, metabolism, homeostasis, cell division, and apoptosis, by modulating protein folding and function [78, 79]. Over 300 types of PTMs are known, but only a few play determinant roles in biological processes [80, 81]. Protein phosphorylation is one of the most common PTMs and exhibits a transient and reversible character, being regulated by the dynamic action of kinases and phosphatases. There are more than hundred thousand potential phosphorylation sites in the human proteome, being estimated that 30–50 % of all proteins are phosphorylated at some point

355 during their lifetime. In eukaryotic systems, phosphorylation
356 occurs essentially at serine and threonine residues, followed by
357 tyrosine, with a ratio of 1,800:200:1 [79, 82, 83]. Phosphorylation
358 events have been associated to a variety of diseases, such as cancer
359 [84], type II diabetes [85], cystic fibrosis [86, 87], neurological
360 diseases such as Parkinson's [88] and Alzheimer's [89], and neu-
361ropsychiatric disorders (e.g., schizophrenia) [90]. The degree of
362 phosphorylation and the localization of specific phosphosites pro-
363 vide meaningful insights to better understand disease-associated
364 signalling pathways, contributing for the development of novel
365 biomarkers and drug targets.

366 Currently, the characterization of phosphoproteins and corre-
367 spondent chemical or proteolytic digests is generally performed
368 using mass spectrometry (MS) techniques. However, this analysis
369 is not always straightforward since phosphopeptides present lower
370 ionization efficiency than their non-phosphorylated counterparts,
371 which results in lower signal intensities in positive ion mode.
372 Moreover, phosphorylated species are usually present at sub-
373 stoichiometric levels and are easily adsorbed by plastics and metals
374 during sample handling [80, 91]. These problems can be partially
375 overcome by using materials with low protein-binding properties
376 and efficient enrichment methods before MS analysis.


377 Enrichment methods are generally based in the affinity capture
378 of the phosphate groups, either by charge interactions (e.g., chro-
379 matofocusing, ion-exchange chromatography), chelation (e.g.,
380 IMAC, metal oxide affinity chromatography (MOAC), hydroxy-
381 apatite, phosphate-binding ligands), or molecular recognition (e.g.,
382 immunoaffinity chromatography, affinity chromatography based in
383 phosphoprotein-binding domains) (Fig. 3). For further details on
384 this subject, the reader should consult recent reviews [79, 92, 93].
385 However, strategies consisting on the chemical modification or
386 replacement of the phosphate moieties by affinity tags are also via-
387 ble alternatives (Fig. 4). Table 4 summarizes the chemical tags used
388 for phosphoprotein and phosphopeptide enrichment.

389 Both phosphoserine (p-Ser) and phosphothreonine (p-Thr)
390 residues undergo β -elimination of phosphoric acid under
391 strong alkaline conditions, yielding dehydroalanine and
392 β -methyldehydroalanine, respectively [94]. These analogues are
393 susceptible to Michael addition by several nucleophiles, such as
394 amine, alcohol, and thiol groups [95]. Oda et al. replaced phos-
395 phate moieties of p-Ser and p-Thr by a biotin affinity tag via a
396 maleimide group, using ethanedithiol (EDT) as a Michael donor
397 and cross-linker. These biotin-labeled peptides were then enriched
398 using avidin chromatography [96]. A similar approach using a
399 phosphoprotein isotope-coded affinity tag (PhIAT) allows the
400 determination and comparative quantification of the phosphoryla-
401 tion sites of proteins, by using either EDT or its deuterated version
402 and a biotinylation reagent—(+)-biotinyliodoacetamidyl-3,6-
403 dioxaoctanediamine. One of the advantages of the latter method
404 is that it does not use maleimide group, which undergoes partial



this figure will be printed in b/w

Fig. 3 Phosphoprotein and phosphopeptide enrichment methods. The most common are based in charge interactions, chelation, molecular recognition, and chemical derivatization



this figure will be printed in b/w

Fig. 4 Phosphopeptide enrichment using chemical tags. B-elimination/Michael addition and phosphoramidate chemistry are the most common chemical derivatization strategies

t4.1 **Table 4**
 t4.2 **List of chemical tags used in phosphoproteomics and their correspondent solid supports**

t4.3	Chemistry	Chemical tag	Solid support	Elution	References	
t4.4	B-Elimination/ Michael addition	Ethanedithiol (EDT)	Avidin resin	Trifluoroacetic acid (TFA)	[96, 97, 100]	
t4.5		coupled to biotin		Dithiothreitol (DTT)	[99]	
t4.6		Engineered biotin tag		Triethylamine (TEA)	[109]	
t4.7		EDT	Thiol-activated	DTT	[101]	
t4.8		Propanedithiol	resins		[102]	
t4.9		EDT	PhIST ^a	UV light	[103]	
t4.10		Cysteamine	PEG-PS resin ^b	TFA	[104]	
t4.11		Guanidinoethanethiol (GET)	–	–	[105, 106]	
t4.12		Fluorescent affinity tag (FAT)	Anti-rhodamine	TFA	[107]	
t4.13			antibodies			
t4.14		Engineered His-tag	Ni ²⁺ -IMAC	Factor Xa	[108]	
t4.15		Carbodiimide condensation	Cystamine	Glass beads with	TFA	[111]
t4.16				iodoacetyl		
t4.17				groups		
t4.18	Cystamine		Glass beads with		[112]	
t4.19			maleimide			
t4.20			groups			
t4.21	Dendrimer	–			[113]	

t4.22 ^aPhIST—aminopropyl beads with a photosensitive linker, a stable isotope-coded leucine moiety, and a thiolate-reactive group

t4.23 ^bPEG-PS resin—polyethyleneglycol-polystyrene copolymer base resin with cystamine as the benzyl carbamate

405 hydrolysis [97]. Biotin-avidin chromatography presents some
 406 drawbacks associated with the nonspecific binding of samples con-
 407 taining endogenous biotin and biotin-binding proteins and the
 408 harsh conditions used during elution, which might denature target
 409 proteins. The utilization of monomeric avidin, which has lower
 410 affinity towards biotin, allows the employment of milder elution
 411 conditions. Yet, a weaker biotin-avidin interaction may lead to an
 412 inefficient capture of biotinylated molecules in the presence of
 413 strong detergents, which are often used to solubilize hydrophobic
 414 molecules, such as membrane proteins [98]. Adamczyk et al. used
 415 a pyridyldithiol-activated biotinylation reagent—biotin-HPDP
 416 (*N*-[6-(biotinamido)hexyl]-3'-(2'-pyridyldithio)propionamide)—
 417 which conjugates via a cleavable disulfide bond, allowing the
 418 reversible biotinylation of the phosphopeptides [99]. However,
 419 this type of reagents may be unstable in some biological condi-
 420 tions. Van der Veken et al. developed an alternative approach by
 421 introducing an acid-labile linker within a biotin-based tag, allow-
 422 ing full recovering of affinity-purified material and elimination of
 423 affinity tag prior to MS analysis [100].

424 Several other tags were developed as alternatives to the biotin-
 425 based ones but still using β -elimination/Michael addition protocols.
 426 Biotin-HPDP can be substituted by different pyridyldithiol-acti-
 427 vated resins, presenting similar reaction mechanisms. Thiol-activated
 428 peptides displace the thiopyridyl group by disulfide exchange, which

rearranges to form a thione [101, 102]. Thaler et al. used propane- 429
dithiol as a Michael donor, possessing six hydrogen atoms instead of 430
the four of EDT, which when replaced by deuteriums provide a 431
higher difference in mass [102]. Using a similar protocol, McLachlin 432
and Chait observed a problematic side reaction in which 1–2 % of 433
the thiol tag was incorporated into non-modified serine residues, 434
since some of these residues undergo β -elimination of water to form 435
dehydroalanine. This will lead to sample enrichment in both phos- 436
phorylated and non-phosphorylated species [101]. 437

A phosphoprotein isotope-coded solid-phase tag (PhIST) was 438
introduced as an improvement of the PhIAT. The biotin tag was 439
replaced by a photosensitive linker covalently bound to aminopro- 440
pyl glass beads, a leucine isotope-coded linker containing six ^{12}C 441
and one ^{14}N (light) or six ^{13}C and one ^{15}N (heavy), and a thiolate- 442
reactive group. β -elimination, Michael addition, tryptic digestion, 443
and solid-phase labeling may be all performed in the same vial. 444
Moreover, the reaction is not affected by the presence of denatur- 445
ants or detergents, and the beads can be thoroughly washed with- 446
out the risk of sample losses, leading to high reaction yields. The 447
bound peptides are simply released by UV photocleavage of the 448
photosensitive linker [103]. 449

Knight et al. converted p-Ser and p-Thr residues into lysine 450
analogues, aminoethylcysteine and β -methylaminoethylcysteine, 451
respectively. As aminoethylcysteine and lysine are isosteres, the 452
modified peptides are then easily cleaved using a LysC endoprote- 453
ase. They successfully enriched the samples in p-Ser by using a 454
polyethyleneglycol-polystyrene (PEG-PS) resin functionalized 455
with a methoxybenzylcarbamate spacer and cystamine. The 456
methoxybenzylcarbamate linkage is stable under the alkaline con- 457
ditions used during β -elimination reaction but is highly acid-labile, 458
allowing peptide release at acidic pH. This methodology allows 459
direct enzymatic cleavage of the peptides at the site of phosphory- 460
lation, which facilitates phosphorylation site mapping [104]. 461

In a different work, p-Ser residues were converted into guan- 462
idinoethylcysteine (Gec), by adding a guanidinoethanethiol 463
(GET) tag to β -eliminated peptides. Gec is recognized as a trypsin 464
cleavage site, providing selective enzymatic digestion and thus 465
facilitating the assignment of phosphorylation sites. Also, the basic 466
guanidine moiety of the tag possesses superior proton affinity, 467
increasing peak intensities in MS [105, 106]. 468

In a one-step reaction, a fluorescent affinity tag (FAT) consist- 469
ing of rhodamine conjugated to a cysteamine moiety selectively 470
modifies p-Ser and p-Thr through a β -elimination/Michael addi- 471
tion strategy. FAT-labeled peptides may then be enriched simply by 472
using commercially available anti-rhodamine affinity columns [107]. 473

His-tag may also be used to chemically derivatize p-Ser- and 474
p-Thr-containing peptides. An engineered His-tag possessing six 475
histidines, a specific recognition site of protease Factor Xa (IEGR), 476

477 a glycine spacer, and a sulfhydryl-containing cysteine residue was
478 used to enrich phosphopeptides by Ni²⁺-IMAC. The thiol group of
479 the side chain of cysteine functioned as a nucleophile in Michael
480 addition reaction. His-tag peptides were then cleaved at the
481 C-terminal side of arginine of the recognition sequence [108].
482 A chemically engineered biotinylated tag, consisting of a biotin
483 group, a base-labile 4-carboxy fluorenylmethoxycarbonyl group,
484 and a sulfhydryl moiety, was developed as a refinement of the pre-
485 viously described His-tag. This engineered biotin tag is smaller and
486 easier to couple and requires mild alkaline conditions instead of the
487 expensive Factor Xa upon release of the peptides [109].

488 Although β -elimination/Michael addition reactions are very
489 well established and straightforward procedures, there are some
490 drawbacks related to their application in phosphoproteomics. First,
491 tyrosine residues are not able to undergo β -elimination. Second,
492 cysteine residues need to be protected by oxidation or alkylation to
493 prevent side reactions. Third, O-glycosylated residues also undergo
494 β -elimination to form dehydroalanil residues, and therefore enzy-
495 matic deglycosylation is recommended to reduce nonspecific label-
496 ing. Fourth, deamidation of asparagine may occur, especially under
497 strong alkaline conditions. Finally, Michael addition might occur at
498 both C α and C β , leading to the formation of epimers [80, 96].

499 Combining both IMAC and β -elimination methods minimizes
500 their individual limitations. Phosphopeptides can be captured
501 using an IMAC resin, which discriminates them from O-glycosylated
502 residues, and then directly eluted by β -elimination. Several chemi-
503 cal tags can be reacted with the β -eliminated peptides, making
504 them easily distinguishable from non-modified peptides that were
505 also bound to the resin [110].

506 Phosphoramidate chemistry is a standard alternative to
507 β -elimination/Michael addition procedures. Zhou et al. used a
508 series of six chemical reactions, involving two carbodiimide-
509 catalyzed condensations. Phosphate groups of the peptides were
510 derivatized with sulfhydryl groups and then captured using iodo-
511 acetyl groups immobilized on glass beads. This method is highly
512 selective and allows the identification of p-Ser, p-Thr, and p-Tyr
513 residues. However, it presents a low recovery yield of approxi-
514 mately 20 % [111].

515 Using a different approach, phosphate groups can be activated
516 using carbodiimide and imidazole and reacted with cystamine to
517 form phosphoramidate bonds in a single step, eliminating the need
518 to protect amine groups on the peptides. After the generation of
519 free thiol groups by reduction, the peptides can be captured using
520 maleimide groups immobilized on glass beads [112]. Using the
521 same chemistry and as an alternative to the solid-phase strategies,
522 phosphorylated peptides can be coupled to a soluble synthetic
523 polyamine (dendrimer), allowing for homogenous reaction [113].

Acknowledgments

524

The authors thank the financial support from Fundação para a Ciência e a Tecnologia through grant no. PEst-C/EQB/LA0006/2011 and contract nos. PTDC/EBB-BIO/102163/2008, PTDC/EBB-BIO/098961/2008, PTDC/EBB-BIO/118317/2010, SFRH/BD/48804/2008 for A.S.P., and SFRH/BD/64427/2009 for I.L.B., as well as to Santander Totta Bank—Universidade Nova de Lisboa for the Scientific Award 2009/2010.

532

References

- [AU 533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
- Woodbury, CP (2006) Recombinant DNA basics. In: Groves MJ (ed) *Pharmaceutical biotechnology*, 2nd edn. Taylor & Francis Group, pp 31–60
 - Young CL, Britton ZT, Robinson AS (2012) Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications. *Biotechnol J* 7:620–634
 - Demain AL, Vaishnav P (2009) Production of recombinant proteins by microbes and higher organisms. *Biotechnol Adv* 27:297–306
 - Malhotra A (2009) Chapter 16 tagging for protein expression. In: Richard RB, Murray PD (eds) *Methods in enzymology: guide to protein purification*, 2nd edn. Academic, pp 239–258
 - Walls D, Loughran ST (2011) Tagging recombinant proteins to enhance solubility and aid purification. In: Walls D, Loughran ST (eds) *Protein chromatography: methods and protocols*. Humana Press, pp 151–175
 - Arnau J, Lauritzen C, Petersen GE et al (2006) Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. *Protein Expr Purif* 48:1–13
 - Nilsson J, Ståhl S, Lundberg J et al (1997) Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. *Protein Expr Purif* 11:1–16
 - Terpe K (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. *Appl Microbiol Biotechnol* 60:523–533
 - Waugh DS (2011) An overview of enzymatic reagents for the removal of affinity tags. *Protein Expr Purif* 80:283–293
 - Fong BA, Wu W-Y, Wood DW (2010) The potential role of self-cleaving purification tags in commercial-scale processes. *Trends Biotechnol* 28:272–279
 - Li Y (2011) Self-cleaving fusion tags for recombinant protein production. *Biotechnol Lett* 33:869–881
 - Smith DB, Johnson KS (1988) Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene* 67:31–40
 - LaVallie ER, Lu Z, Diblasio-Smith EA et al (2000) Thioredoxin as a fusion partner for production of soluble recombinant proteins in *Escherichia coli*. In: Thorner J, Emr SD, Abelson JN (eds) *Applications of chimeric genes and hybrid proteins: gene expression and protein purification*. Academic, pp 322–340
 - Kaplan W, Erhardt J, Sluis-Cremer N et al (1997) Conformational stability of pGEX-expressed *Sehistosoma japonicum* glutathione S-transferase: a detoxification enzyme and fusion-protein affinity tag. *Protein Sci* 6:399–406
 - Frangioni JV, Neel BG (1993) Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. *Anal Biochem* 210:179–187
 - Singh CR, Asano K (2007) Localization and characterization of protein–protein interaction sites. In: Jon L (ed) *Methods in enzymology: translation initiation: extract systems and molecular genetics*. Academic, pp 139–161
 - Nikaido H (1994) Maltose transport system of *Escherichia coli*: an ABC-type transporter. *FEBS Lett* 346:55–58
 - Kellermann OK, Ferenci T (1982) Maltose-binding protein from *Escherichia coli*. In: Willis AW (ed) *Methods in enzymology—carbohydrate metabolism—part E*. Academic, pp 459–463
 - di Guana C, Lib P, Riggsa PD et al (1988) Vectors that facilitate the expression and purification of foreign peptides in *Escherichia coli* by fusion to maltose-binding protein. *Gene* 67:21–30
 - Fox JD, Waugh DS (2003) Maltose-binding protein as a solubility enhancer. In: Vaillancourt PE (ed) *Methods in molecular biology—E. coli gene expression protocols*. Humana Press, Totowa, NJ, pp 99–117
 - Kapust RB, Waugh DS (1999) *Escherichia coli* maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. *Protein Sci* 8:1668–1674
- 579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624

- 625 22. Katti SK, LeMaster DM, Eklund H (1990) 686
626 Crystal structure of thioredoxin from 687
627 *Escherichia coli* at 1.68 Å resolution. J Mol 688
628 Biol 212:167–184 689
- 629 23. LaVallie ER, DiBlasio EA, Kovacic S et al 690
630 (1993) A thioredoxin gene fusion expression 691
631 system that circumvents inclusion body forma- 692
632 tion in the *E. coli* cytoplasm. Nat 693
633 Biotechnol 11:187–193 694
- 634 24. Marblestone JG, Edavettal SC, Lim Y et al 695
635 (2006) Comparison of SUMO fusion technol- 696
636 ogy with traditional gene fusion systems: 697
637 enhanced expression and solubility with 698
638 SUMO. Protein Sci 15:182–189 699
- 639 25. Li S-J, Hochstrasser M (1999) A new protease 700
640 required for cell-cycle progression in 701
641 yeast. Nature 398:246–251 702
- 642 26. Panavas T, Sanders C, Butt RT (2009) 703
643 SUMO fusion technology for enhanced pro- 704
644 tein production in prokaryotic and eukaryotic 705
645 expression systems. In: Ulrich HD (ed) 706
646 SUMO protocols methods in molecular biol- 707
647 ogy. Humana Press, pp 303–317 708
- 648 27. Malakhov M, Mattern M, Malakhova O et al 709
649 (2004) SUMO fusions and SUMO-specific 710
650 protease for efficient expression and purifica- 711
651 tion of proteins. J Struct Funct Genomics 712
652 5:75–86 713
- 653 28. Gusarov I, Nudler E (2001) Control of intrinsic 714
654 transcription termination by N and NusA: 715
655 the basic mechanisms. Cell 107:437–449 716
- 656 29. Liu K, Hanna MM (1995) NusA contacts 717
657 nascent RNA in *Escherichia coli* transcription 718
658 complexes. J Mol Biol 247:547–558 719
- 659 30. Cohen SE, Lewis CA, Mooney RA et al 720
660 (2010) Roles for the transcription elongation 721
661 factor NusA in both DNA repair and damage 722
662 tolerance pathways in *Escherichia coli*. Proc 723
663 Natl Acad Sci U S A 107:15517–15522 724
- 664 31. Harrison RG (2000) Expression of soluble 725
665 heterologous proteins via fusion with NusA 726
666 protein. Innovations 11:4–7 727
- 667 32. Davis GD, Elisei C, Newham DM et al 728
668 (1999) New fusion protein systems designed 729
669 to give soluble expression in *Escherichia coli*. 730
670 Biotechnol Bioeng 65:382–388 731
- 671 33. Nilsson B, Abrahmsén L (1990) Fusions to 732
672 staphylococcal protein A. Methods Enzymol 733
673 185:144–161 734
- 674 34. Eklund M, Axelsson L, Uhlén M et al (2002) 735
675 Anti-idiotypic protein domains selected from 736
676 protein A-based affibody libraries. Proteins 737
677 48:454–462 738
- 678 35. Nilsson B, Abrahmsén L, Uhlén M (1985) 739
679 Immobilization and purification of enzymes 740
680 with staphylococcal protein A gene fusion 741
681 vectors. EMBO J 4:1075–1080 742
- 682 36. Nilsson B, Moks T, Jansson B et al (1987) A 743
683 synthetic IgG-binding domain based on 744
684 staphylococcal protein A. Protein Eng 1: 745
685 107–113 746
37. Hedhammar M, Alm T, Gräslund T et al 686
(2006) Single-step recovery and solid-phase 687
refolding of inclusion body proteins using a 688
polycationic purification tag. Biotechnol J 689
1:187–196 690
38. Hedhammar M, Gräslund T, Uhlén M et al 691
(2004) Negatively charged purification tags 692
for selective anion-exchange recovery. Protein 693
Eng Des Sel 17:779–786 694
39. Porath J, Carlsson JAN, Olsson I et al (1975) 695
Metal chelate affinity chromatography, a new 696
approach to protein fractionation. Nature 697
258:598–599 698
40. Hochuli E, Döbeli H, Schacher A (1987) 699
New metal chelate adsorbent selective for pro- 700
teins and peptides containing neighbouring 701
histidine residues. J Chromatogr 18:177–184 702
41. Hochuli E, Bannwarth W, Döbeli H et al 703
(1988) Genetic approach to facilitate purifica- 704
tion of recombinant proteins with a novel 705
metal chelate adsorbent. Nat Biotechnol 706
6:1321–1325 707
42. Block H, Maertens B, Priestersbach A et al 708
(2009) Immobilized-metal affinity chroma- 709
tography (IMAC): a review. Methods 710
Enzymol 463:439–473 711
43. Gaberc-Porekar V, Menart V (2001) 712
Perspectives of immobilized-metal affinity 713
chromatography. J Biochem Biophys Methods 714
49:335–360 715
44. Gutiérrez R, Martín del Valle EM, Galán MA 716
(2007) Immobilized metal-ion affinity chroma- 717
tography: status and trends. Sep Purif Rev 718
36:71–111 719
45. Dashivets T, Wood N, Hergersberg C et al 720
(2009) Rapid matrix-assisted refolding of 721
histidine-tagged proteins. Chembiochem 10: 722
869–876 723
46. Kato K, Sato H, Iwata H (2005) 724
Immobilization of histidine-tagged recombi- 725
nant proteins onto micropatterned surfaces 726
for cell-based functional assays. Langmuir 727
21:7071–7075 728
47. Wegner GJ, Lee HJ, Marriott G et al (2003) 729
Fabrication of histidine-tagged fusion protein 730
arrays for surface plasmon resonance imaging 731
studies of protein–protein and protein–DNA 732
interactions. Anal Chem 75:4740–4746 733
48. Wilson DS, Nock S (2002) Functional pro- 734
tein microarrays. Curr Opin Chem Biol 6: 735
81–85 736
49. Mooney JT, Fredericks D, Hearn MTW 737
(2011) Use of phage display methods to iden- 738
tify heptapeptide sequences for use as affinity 739
purification ‘tags’ with novel chelating ligands 740
in immobilized metal ion affinity chromatog- 741
raphy. J Chromatogr A 1218:92–99 742
50. Einhauer A, Jungbauer A (2001) The FLAG™ 743
peptide, a versatile fusion tag for the purifica- 744
tion of recombinant proteins. J Biochem 745
Biophys Methods 49:455–465 746

- 747 51. Evan GI, Lewis GK, Ramsay G et al (1985) 808
 748 Isolation of monoclonal antibodies specific 809
 749 for human c-myc proto-oncogene product. 810
 750 Mol Cell Biol 5:3610–3616 811
- 751 52. Chatterjee DK, Esposito D (2006) Enhanced 812
 752 soluble protein expression using two new 813
 753 fusion tags. Protein Expr Purif 46:122–129 814
- 754 53. Studier FW, Moffatt BA (1986) Use of bacte- 815
 755 riophage T7 RNA polymerase to direct selec- 816
 756 tive high-level expression of cloned genes. 817
 757 J Mol Biol 189:113–130 818
- 758 54. Burgess RR, Thompson NE (2002) Advances 819
 759 in gentle immunoaffinity chromatography. 820
 760 Curr Opin Biotechnol 13:304–308 821
- 761 55. Thompson NE, Arthur TM, Burgess RR 822
 762 (2003) Development of an epitope tag for the 823
 763 gentle purification of proteins by immunoaf- 824
 764 finity chromatography: application to epitope- 825
 765 tagged green fluorescent protein. Anal 826
 766 Biochem 323:171–179 827
- 767 56. Edwards AM, Darst SA, Feaver WJ et al 828
 768 (1990) Purification and lipid-layer crystalliza- 829
 769 tion of yeast RNA polymerase II. Proc Natl 830
 770 Acad Sci U S A 87:2122–2126 831
- 771 57. Duellman SJ, Thompson NE, Burgess RR 832
 772 (2004) An epitope tag derived from human 833
 773 transcription factor IIB that reacts with a 834
 774 polyol-responsive monoclonal antibody. 835
 775 Protein Expr Purif 35:147–155 836
- 776 58. Kim JS, Raines RT (1993) Ribonuclease 837
 777 S-peptide as a carrier in fusion proteins. 838
 778 Protein Sci 2:348–356 839
- 779 59. Karpeisky MY, Senchenko VN, Dianova MV 840
 780 et al (1994) Formation and properties of 841
 781 S-protein complex with S-peptide-containing 842
 782 fusion protein. FEBS Lett 339:209–212 843
- 783 60. Vaillancourt P, Zheng C-F, Hoang DQ et al 844
 784 (2000) Affinity purification of recombinant 845
 785 proteins fused to calmodulin or to calmodulin- 846
 786 binding peptides. In: Thorner J, Emr SD, 847
 787 Abelson JN (eds) Methods in enzymology. 848
 788 Academic, pp 340–362 849
- 789 61. Melkko S, Neri D (2003) Calmodulin as an 850
 790 affinity purification tag. In: Vaillancourt P (ed) 851
 791 Methods in molecular biology—*E. coli* gene 852
 792 expression protocols. Academic, pp 69–77 853
- 793 62. Stofko-Hahn RE, Carr DW, Scott JD (1992) 854
 794 A single step purification for recombinant 855
 795 proteins. Characterization of a microtubule 856
 796 associated protein (MAP 2) fragment which 857
 797 associates with the type II cAMP-dependent 858
 798 protein kinase. FEBS Lett 302:274–278 859
- 799 63. Zheng C-F, Simcox T, Xu L et al (1997) 860
 800 A new expression vector for high level 861
 801 protein production, one step purification 862
 802 and direct isotopic labeling of calmodulin- 863
 803 binding peptide fusion proteins. Gene 186: 864
 804 55–60 865
- 805 64. Neri D, de Lalla C, Petrul H et al (1995) 866
 806 Calmodulin as a versatile tag for antibody 867
 807 fragments. Nat Biotechnol 13:373–377 868
65. Schmidt TGM, Skerra A (1993) The random 808
 peptide library-assisted engineering of a 809
 C-terminal affinity peptide, useful for the 810
 detection and purification of a functional Ig 811
 Fv fragment. Protein Eng 6:109–122 812
66. Skerra A, Schmidt TGM (2000) Use of the 813
 Strep-tag and streptavidin for detection and 814
 purification of recombinant proteins. In: 815
 Jeremy Thorner SDEJNA (ed) Methods in 816
 enzymology: applications of chimeric genes 817
 and hybrid proteins part a: gene expression and 818
 protein purification. Academic, pp 271–304 819
67. Schmidt TGM, Koepke J, Frank R et al 820
 (1996) Molecular interaction between the 821
 strep-tag affinity peptide and its cognate tar- 822
 get, streptavidin. J Mol Biol 255:753–766 823
68. Korndörfer IP, Skerra A (2002) Improved 824
 affinity of engineered streptavidin for the 825
 Strep-tag II peptide is due to a fixed open 826
 conformation of the lid-like loop at the bind- 827
 ing site. Protein Sci 11:883–893 828
69. Voss S, Skerra A (1997) Mutagenesis of a flex- 829
 ible loop in streptavidin leads to higher affini- 830
 ty for the Strep-tag II peptide and improved 831
 performance in recombinant protein purifica- 832
 tion. Protein Eng 10:975–982 833
70. Schmidt TGM, Skerra A (2007) The Strep- 834
 tag system for one-step purification and high- 835
 affinity detection or capturing of proteins. 836
 Nat Protoc 2:1528–1535 837
71. Keefe AD, Wilson DS, Seelig B et al (2001) 838
 One-step purification of recombinant pro- 839
 teins using a nanomolar-affinity streptavidin- 840
 binding peptide, the SBP-tag. Protein Expr 841
 Purif 23:440–446 842
72. Wilson DS, Keefe AD, Szostak JW (2001) 843
 The use of mRNA display to select high- 844
 affinity protein-binding peptides. Proc Natl 845
 Acad Sci U S A 98:3750–3755 846
73. Choi S II, Song HW, Moon JW et al (2001) 847
 Recombinant enterokinase light chain with 848
 affinity tag: expression from *Saccharomyces 849*
cerevisiae and its utilities in fusion protein 850
 technology. Biotechnol Bioeng 75:718–724 851
74. Dougherty WG, Carrington JC, Cary SM 852
 et al (1988) Biochemical and mutational anal- 853
 ysis of a plant virus polyprotein cleavage site. 854
 EMBO J 7:1281–1287 855
75. Jenny RJ, Mann KG, Lundblad RL (2003) A 856
 critical review of the methods for cleavage of 857
 fusion proteins with thrombin and factor Xa. 858
 Protein Expr Purif 31:1–11 859
76. Chang J-Y (1985) Thrombin specificity. Eur J 860
 Biochem 151:217–224 861
77. Yuan L-D, Hua Z-C (2002) Expression, purifi- 862
 cation, and characterization of a biologically 863
 active bovine enterokinase catalytic subunit in 864
Escherichia coli. Protein Expr Purif 25:300–304 865
78. Tichy A, Salovska B, Rehulka P et al (2011) 866
 Phosphoproteomics: searching for a needle in 867
 a haystack. J Proteomics 74:2786–2797 868

- 869 79. Thingholm TE, Jensen ON, Larsen MR (2009) Analytical strategies for phosphoproteomics. *Proteomics* 9:1451–1468
870
871
- 872 80. Witze ES, Old WM, Resing KA et al (2007) Mapping protein post-translational modifications with mass spectrometry. *Nat Methods* 4:798–806
873
874
875
- 876 81. Jensen ON (2006) Interpreting the protein language using proteomics. *Nat Rev Mol Cell Biol* 7:391–403
877
878
- 879 82. Reinders J, Sickmann A (2005) State-of-the-art in phosphoproteomics. *Proteomics* 5:4052–4061
880
881
- 882 83. Paradelo A, Albar JP (2008) Advances in the analysis of protein phosphorylation. *J Proteome Res* 7:1809–1818
883
884
- 885 84. Harsha HC, Pandey A (2010) Phosphoproteomics in cancer. *Mol Oncol* 4:482–495
886
- 887 85. Højlund K, Wrzesinski K, Larsen PM et al (2003) Proteome analysis reveals phosphorylation of ATP synthase β -subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. *J Biol Chem* 278:10436–10442
888
889
890
891
892
- 893 86. Levitan IB (1994) Modulation of ion channels by protein phosphorylation and dephosphorylation. *Annu Rev Physiol* 56:193–212
894
895
896
- 897 87. Davis MJ, Wu X, Nurkiewicz TR et al (2001) Regulation of ion channels by protein tyrosine phosphorylation. *Am J Physiol Heart Circ Physiol* 281:H1835–H1862
898
899
900
- 901 88. Gloeckner CJ, Boldt K, von Zweydford F et al (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. *J Proteome Res* 9:1738–1745
902
903
904
905
906
- 907 89. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med* 15:112–119
908
909
910
- 911 90. Schwarz E, Bahn S (2008) Biomarker discovery in psychiatric disorders. *Electrophoresis* 29:2884–2890
912
913
- 914 91. Mann M, Ong S-E, Grønborg M et al (2002) Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. *Trends Biotechnol* 20:261–268
915
916
917
- 918 92. Schmidt SR, Schweikart F, Andersson ME (2007) Current methods for phosphoprotein isolation and enrichment. *J Chromatogr B* 849:154–162
919
920
921
- 922 93. Batalha IL, Lowe CR, Roque ACA (2012) Platforms for enrichment of phosphorylated proteins and peptides in proteomics. *Trends Biotechnol* 30:100–110
923
924
925
- 926 94. Byford MF (1991) Rapid and selective modification of phosphoserine residues catalysed by Ba²⁺ ions for their detection during peptide microsequencing. *Biochem J* 280:261–265
927
928
929
- 930 95. Meyer HE, Hoffmann-Posorske E, Korte H et al (1986) Sequence analysis of phosphoserine-containing peptides. Modification for picomolar sensitivity. *FEBS Lett* 204:61–66
931
932
933
- 934 96. Oda Y, Nagasu T, Chait BT (2001) Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. *Nat Biotechnol* 19:379–382
935
936
937
- 938 97. Goshe MB, Conrads TP, Panisko EA et al (2001) Phosphoprotein isotope-coded affinity tag approach for isolating and quantitating phosphopeptides in proteome-wide analyses. *Anal Chem* 73:2578–2586
939
940
941
942
- 943 98. Rybak J-N, Scheurer SB, Neri D et al (2004) Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. *Proteomics* 4:2296–2299
944
945
946
- 947 99. Adamczyk M, Gebler JC, Wu J (2001) Selective analysis of phosphopeptides within a protein mixture by chemical modification, reversible biotinylation and mass spectrometry. *Rapid Commun Mass Spectrom* 15:1481–1488
948
949
950
951
- 952 100. Van der Veken P, Dirksen EHC, Ruijter E et al (2005) Development of a Novel Chemical Probe for the Selective Enrichment of Phosphorylated Serine- and Threonine-Containing Peptides. *Chembiochem* 6:2271–2280
953
954
955
956
- 957 101. McLachlin DT, Chait BT (2003) Improved β -elimination-based affinity purification strategy for enrichment of phosphopeptides. *Anal Chem* 75:6826–6836
958
959
960
- 961 102. Thaler F, Valsasina B, Baldi R et al (2003) A new approach to phosphoserine and phosphothreonine analysis in peptides and proteins: chemical modification, enrichment via solid-phase reversible binding, and analysis by mass spectrometry. *Anal Bioanal Chem* 376:366–373
962
963
964
965
966
967
- 968 103. Qian W-J, Goshe MB, Camp DG II et al (2003) Phosphoprotein isotope-coded solid-phase tag approach for enrichment and quantitative analysis of phosphopeptides from complex mixtures. *Anal Chem* 75(5441):5450
969
970
971
972
- 973 104. Knight ZA, Schilling B, Row RH et al (2003) Phosphospecific proteolysis for mapping sites of protein phosphorylation. *Nat Biotechnol* 21:1047–1054
974
975
976
- 977 105. Ahn YH, Ji ES, Lee JY et al (2007) Coupling of TiO₂-mediated enrichment and on-bead guanidinoethanethiol labeling for effective phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* 21:3987–3994
978
979
980
981
982
- 983 106. Ahn YH, Ji ES, Kwon KH et al (2007) Protein phosphorylation analysis by site-specific arginine-mimic labeling in gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Anal Biochem* 370:77–86
984
985
986
987
988
- 989 107. Stevens SM Jr, Chung AY, Chow MC et al (2005) Enhancement of phosphoprotein
990

- 991 analysis using a fluorescent affinity tag and
992 mass spectrometry. *Rapid Commun Mass*
993 *Spectrom* 19:2157–2162
- 994 108. Jalili PR, Sharma D, Ball HL (2007)
995 Enhancement of ionization efficiency and
996 selective enrichment of phosphorylated pep-
997 tides from complex protein mixtures using a
998 reversible poly-histidine tag. *J Am Soc Mass*
999 *Spectrom* 18:1007–1017
- 1000 109. Jalili PR, Ball HL (2008) Novel reversible bio-
1001 tinylated probe for the selective enrichment of
1002 phosphorylated peptides from complex mix-
1003 tures. *J Am Soc Mass Spectrom* 19:741–750
- 1004 110. Thompson AJ, Hart SR, Franz C et al (2003)
1005 Characterization of protein phosphorylation
1006 by mass spectrometry using immobilized
1007 metal ion affinity chromatography with on-
1008 resin β -elimination and Michael addition.
1009 *Anal Chem* 75:3232–3243
- 1010 111. Zhou H, Watts JD, Aebersold R (2001) A sys-
1011 tematic approach to the analysis of protein
1012 phosphorylation. *Nat Biotechnol* 19:375–378
- 1013 112. Bodenmiller B, Mueller LN, Pedrioli PGA
1014 et al (2007) An integrated chemical, mass
1015 spectrometric and computational strategy for
1016 (quantitative) phosphoproteomics: applica-
1017 tion to *Drosophila melanogaster* Kc167 cells.
1018 *Mol Biosyst* 3:275–286
- 1019 113. Tao WA, Wollscheid B, O'Brien R et al (2005)
1020 Quantitative phosphoproteome analysis using a
1021 dendrimer conjugation chemistry and tandem
1022 mass spectrometry. *Nat Methods* 2:591–598
- 1023 114. Ullmann A (1984) One-step purification of
1024 hybrid proteins which have β -galactosidase
1025 activity. *Gene* 29:27–31
- 1026 115. Dykes CW, Bookless AB, Coomber BA et al
1027 (1988) Expression of atrial natriuretic factor
1028 as a cleavable fusion protein with chloram-
1029 phenicol acetyltransferase in *Escherichia coli*.
1030 *Eur J Biochem* 174:411–416
- 1031 116. Sjölander A, Nygrén P-Å, Ståhl S et al (1997)
1032 The serum albumin-binding region of strep-
1033 tococcal protein G: a bacterial fusion partner
1034 with carrier-related properties. *J Immunol*
1035 *Methods* 201:115–123
- 1036 117. Anba J, Baty D, Llobès R et al (1987)
1037 Expression vector promoting the synthesis and
1038 export of the human growth-hormone-releasing
1039 factor in *Escherichia coli*. *Gene* 53:219–226
- 1040 118. Tomme P, Boraston A, McLean B et al (1998)
1041 Characterization and affinity applications of
1042 cellulose-binding domains. *J Chromatogr B*
1043 *Biomed Sci Appl* 715:283–296
- 1044 119. Luoqing C, Ford C, Nikolov Z (1991)
1045 Adsorption to starch of a β -galactosidase fusion
1046 protein containing the starch-binding region of
1047 *Aspergillus glucoamylase*. *Gene* 99:121–126
- 1048 120. Ong E, Greenwood JM, Gilkes NR et al
1049 (1989) The cellulose-binding domains of cel-
1050 lulases: tools for biotechnology. *Trends*
1051 *Biotechnol* 7:239–243
121. Thorn KS, Naber N, Matuska M et al (2000) 1052
A novel method of affinity-purifying proteins 1053
using a bis-arsenical fluorescein. *Protein Sci* 1054
9:213–217 1055
122. Chaga G, Bochkariov DE, Jokhadze GG et al 1056
(1999) Natural poly-histidine affinity tag for 1057
purification of recombinant proteins on 1058
cobalt(II)-carboxymethylaspartate crosslinked 1059
agarose. *J Chromatogr A* 864:247–256 1060
123. Sassenfeld HM, Brewer SJ (1984) A polypep- 1061
tide fusion designed for the purification of 1062
recombinant proteins. *Nat Biotechnol* 2:76–81 1063
124. Stubenrauch K, Bachmann A, Rudolph R 1064
et al (2000) Purification of a viral coat protein 1065
by an engineered polyionic sequence. 1066
J Chromatogr B Biomed Sci Appl 737:77–84 1067
125. Zhao BJ, Ford CF, Glatz CE et al (1990) 1068
Polyelectrolyte precipitation of β -galactosidase 1069
fusions containing poly-aspartic acid tails. 1070
J Biotechnol 14:273–283 1071
126. Dalboge H, Dahl H-HM, Pedersen J et al 1072
(1987) A novel enzymatic method for pro- 1073
duction of authentic hGH from an *Escherichia* 1074
coli produced hGH-precursor. *Nat Biotechnol* 1075
5:161–164 1076
127. Persson M, Bergstrand MG, Bülow L et al 1077
(1988) Enzyme purification by genetically 1078
attached polycysteine and polyphenylalanine 1079
affinity tails. *Anal Biochem* 172:330–337 1080
128. Hopp TP, Prickett KS, Price VL et al (1988) 1081
A short polypeptide marker sequence useful 1082
for recombinant protein identification and 1083
purification. *Nat Biotechnol* 6:1204–1210 1084
129. Schatz PJ (1993) Use of peptide libraries to 1085
map the substrate specificity of a peptide- 1086
modifying enzyme: a 13 residue consensus 1087
peptide specifies biotinylation in *Escherichia* 1088
coli. *Nat Biotechnol* 11:1138–1143 1089
130. Lamla T, Stiege W, Erdmann VA (2002) An 1090
improved protein bioreactor. *Mol Cell* 1091
Proteomics 1:466–471 1092
131. Smith JC, Derbyshire RB, Cook E et al 1093
(1984) Chemical synthesis and cloning of a 1094
poly(arginine)-coding gene fragment 1095
designed to aid polypeptide purification. 1096
Gene 32:321–327 1097
132. Goeddel DV, Kleid DG, Bolivar F et al (1979) 1098
Expression in *Escherichia coli* of chemically 1099
synthesized genes for human insulin. *Proc* 1100
Natl Acad Sci U S A 76:106–110 1101
133. Moks T, Abrahmsen L, Holmgren E et al 1102
(1987) Expression of human insulin-like 1103
growth factor I in bacteria: use of optimized 1104
gene fusion vectors to facilitate protein purifi- 1105
cation. *Biochemistry* 26:5239–5244 1106
134. Huston JS, Levinson D, Mudgett-Hunter M 1107
et al (1988) Protein engineering of antibody 1108
binding sites: recovery of specific activity in an 1109
anti-digoxin single-chain Fv analogue pro- 1110
duced in *Escherichia coli*. *Proc Natl Acad Sci* 1111
U S A 85:5879–5883 1112

Author Queries

Chapter No.: 14 0002077658

Queries	Details Required	Author's Response
AU1	Please check the term "Thiogalactosidyl" for correctness.	
AU2	Please check if edit to sentence starting "The main applications..." is okay.	
AU3	Please check if the term "dehydroanalanyl" should be changed to "dehydroalanine".	
AU4	Please provide publisher's location in references [1, 4, 5, 13, 16, 18, 26, 60, 61, and 66].	

Uncorrected Proof